Last reviewed 2026-05-27 · How we verify

rebecsinib

Aspera Biomedicines, Inc. · Phase 1 active Small molecule ✓ Verified May 2026

rebecsinib is a Small molecule drug developed by Aspera Biomedicines, Inc.. It is currently in Phase 1 development. Also known as: 17S-FD-895.

Rebecsinib is an experimental anticancer medication that inhibits ADAR1 by modulating the spliceosome. It is being studied in clinical trials for the treatment of secondary acute myeloid leukemia and high-risk myelofibrosis.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	rebecsinib
Also known as	17S-FD-895
Sponsor	Aspera Biomedicines, Inc.
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

rebecsinib CI brief — competitive landscape report
rebecsinib updates RSS · CI watch RSS
Aspera Biomedicines, Inc. portfolio CI

Frequently asked questions about rebecsinib

What is rebecsinib?

rebecsinib is a Small molecule drug developed by Aspera Biomedicines, Inc..

Who makes rebecsinib?

rebecsinib is developed by Aspera Biomedicines, Inc. (see full Aspera Biomedicines, Inc. pipeline at /company/aspera-biomedicines-inc).

Is rebecsinib also known as anything else?

rebecsinib is also known as 17S-FD-895.

What development phase is rebecsinib in?

rebecsinib is in Phase 1.

Manufacturer: Aspera Biomedicines, Inc. — full pipeline
Therapeutic area: All drugs in Other
Also known as: 17S-FD-895

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing